<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00515801</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB 57/07 SB</org_study_id>
    <nct_id>NCT00515801</nct_id>
  </id_info>
  <brief_title>Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DM</brief_title>
  <official_title>Effect of a Sulfonylurea Compound on the Glucagon Response to Insulin-induced Hypoglycemia in Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to demonstrate that oral administration of glibenclamide stimulates pancreatic
      glucagon secretion during hypoglycemia in insulin-deficient (C-peptide negative) patients
      with type 1 diabetes when compared to type 1 diabetic patients with residual insulin
      secretion (C-peptide positive).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The glucagon response during insulin induced hypoglycemia and rate of glucose recovery will
      be monitored in 10 C-peptide positive and 10 C-Peptide negative patients with type 1 DM
      following the application of glibenclamide and placebo in a randomized, single-blind,
      cross-over study.

      Cognitive function during hypoglycemia with and without glibenclamide pretreatment will be a
      secondary outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma glucagon concentrations during insulin induced hypoglycemia with and without glibenclamide pretreatment</measure>
    <time_frame>cross-sectional</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of glucose recovery following insulin induced hypoglycemia with and without glibenclamide pretreatment</measure>
    <time_frame>cross-sectional</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive function during insulin induced hypoglycemia with and without glibenclamide pretreatment</measure>
    <time_frame>cross-sectional</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glibenclamide 5 mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glibenclamide</intervention_name>
    <description>glibenclamide 15 mg single dose</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Daonil 5 mg pills</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsules, single dose</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 to 50 years

          -  Patients diagnosed with C-peptide negative diabetes type 1 (C-peptide &lt;200 pmol/L 6
             min after 1 mg glucagon i.v. at plasma glucose concentrations between 5 and 11 mmol/l)

          -  Patients diagnosed with C-peptide positive diabetes type 1 (C-peptide &gt; 500 pmol/l 6
             min after 1 mg glucagon i.v. at plasma glucose concentrations between 5 and 11 mmol/l)

          -  Stable metabolic control; HbA1c levels &lt;8.0 % and without episodes of antecedent
             severe hypoglycemias in the past four weeks

        Exclusion Criteria:

          -  Patients treated with medications potentially interfering with glucose metabolism,
             such as systemic steroids, immunosuppressive drugs (cyclosporine, tacrolimus,
             sirolimus), highly active antiretroviral therapy

          -  History coronary artery disease

          -  History of epilepsy or seizures

          -  Current smokers

          -  Any significant or unstable hepatic, cardiac, pulmonary, renal, neurological,
             musculoskeletal, hematological or endocrine disease.

          -  Pregnant or breast feeding women

          -  Woman of childbearing potential not using a reliable method of birth control such as
             oral contraceptives or IUD.

          -  Subjects refusing or unable to give written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Bilz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2007</study_first_submitted>
  <study_first_submitted_qc>August 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2007</study_first_posted>
  <last_update_submitted>March 8, 2012</last_update_submitted>
  <last_update_submitted_qc>March 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes mellitus type 1</keyword>
  <keyword>hypoglycemia</keyword>
  <keyword>sulfonylurea</keyword>
  <keyword>glucagon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

